Bright Minds Biosciences to Present Data at the American Epilepsy Society 2024 Annual Meeting- Poster presentations on BMB-101 will focus on 5-HT2C functional selectivity and Phase 1 clinical data -
Bright Minds Biosciences Closes US$35 Million Non-Brokered Private PlacementVANCOUVER, British Columbia, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (
NASDAQDRUG) (“Bright Minds” or the “Company”) announces that further to its news release of October 18, 2024, the Company has closed a non-brokered private placement of 1,612,902 common shares in the capital of the Company (“Shares”) at a price of USD$21.70 per Share for aggregate gross proceeds of USD$35,000,000 (the “Offering”).
Bright Minds Biosciences and Firefly Neuroscience to Collaborate After the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy for Full Analysis of EEG DataNEW YORK AND VANCOUVER, British Columbia, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (Bright Minds or the Company) (
NASDAQDRUG), a biotechnology company focused on developing novel therapies for neurological and neuropsychiatric disorders, today announced that it is once again collaborating with Firefly Neuroscience, Inc. (Firefly)
NASDAQ: AIFFNASDAQAIFF)
Bright Minds Biosciences proprietary compound, BMB-201, 5-HT2C/2A mixed agonist, demonstrated similar efficacy to morphine in preclinical pain modelsNEW YORK, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (
NASDAQDRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other CNS disorders, is excited to announce positive data from the preclinical testing of BMB-201 completed with National Institute of Health pain screening (PSPP) program.
Bright Minds Biosciences announces participation in upcoming scientific conferences and partnering eventsNEW YORK, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (
NASDAQDRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other CNS disorders, is excited to announce its participation in the upcoming scientific conferences:
Bright Minds Biosciences to Host Investor & Analyst KOL Event on September 25thNEW YORK, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (NASDAQ / CSE: DRUG) announces the Key Opinion Leader (KOL) event with leading experts in epilepsy research and treatment. The event will include Dr. Dennis Dlugos, Dr. Joe Sullivan, and Dr. Jo Sourbron, who will provide critical insights into the evolving landscape of drug-resistant seizures and the unmet needs in epilepsy care. These thought leaders will explore the scientific innovations driving the Phase 2 BREAKTHROUGH clinical trial design announced last week and highlight the potential for novel treatments.
